Published in Front Neurol on September 25, 2017
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science (2005) 14.43
The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci (1999) 9.95
Structural and functional features of central nervous system lymphatic vessels. Nature (2015) 8.73
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov (2010) 5.55
Diffusion tensor imaging of the brain. Neurotherapeutics (2007) 5.37
Immune function of microglia. Glia (2001) 4.59
The interleukin-1 family: back to the future. Immunity (2013) 3.90
Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol (2006) 3.39
A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler (2008) 2.28
Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. Nat Rev Neurosci (2014) 2.25
Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology (2010) 2.03
Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol (1994) 1.97
COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol (2006) 1.87
Microglial activation and chronic neurodegeneration. Neurotherapeutics (2010) 1.87
Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation (2014) 1.83
Alternative activation of macrophages: immune function and cellular biology. Immunobiology (2009) 1.82
Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci (2002) 1.80
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med (1999) 1.79
Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy. J Neurol (2009) 1.67
Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc Natl Acad Sci U S A (2010) 1.60
C9orf72 is required for proper macrophage and microglial function in mice. Science (2016) 1.46
Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med (2012) 1.42
Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev (2009) 1.41
Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer (2007) 1.40
Expanding the mind: insulin-like growth factor I and brain development. Endocrinology (2008) 1.39
Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci (2006) 1.34
The microglial-motoneuron dialogue in ALS. Acta Myol (2011) 1.31
Inflammation, demyelination, and degeneration - recent insights from MS pathology. Biochim Biophys Acta (2010) 1.20
Decoding ALS: from genes to mechanism. Nature (2016) 1.18
Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med (2004) 1.15
Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol (2014) 1.12
Suppression of nuclear factor-κB activation and inflammation in microglia by physically modified saline. J Biol Chem (2012) 1.06
Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Mult Scler (2004) 1.00
Novel roles for Nogo receptor in inflammation and disease. Trends Neurosci (2008) 0.98
Metabolic profiling distinguishes three subtypes of Alzheimer's disease. Aging (Albany NY) (2015) 0.98
Protection of Tregs, suppression of Th1 and Th17 cells, and amelioration of experimental allergic encephalomyelitis by a physically-modified saline. PLoS One (2012) 0.97
Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis. J Neuroinflammation (2011) 0.96
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler (2009) 0.96
Preliminary investigation of effect of granulocyte colony stimulating factor on amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2009) 0.95
G-CSF prevents the progression of structural disintegration of white matter tracts in amyotrophic lateral sclerosis: a pilot trial. PLoS One (2011) 0.95
Alterations of T cell subsets in ALS: a systemic immune activation? Acta Neurol Scand (2011) 0.94
Intrathecal cyclosporin prolongs survival of late-stage ALS mice. Brain Res (2001) 0.94
Insulin and IGF receptor signalling in neural-stem-cell homeostasis. Nat Rev Endocrinol (2014) 0.93
Amyotrophic lateral sclerosis. Associated clinical disorders and immunological evaluations. Arch Neurol (1986) 0.93
Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph Lateral Scler (2009) 0.93
The Neuroinflammatory Response in ALS: The Roles of Microglia and T Cells. Neurol Res Int (2012) 0.90
Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy. Arch Neurol (1994) 0.89
Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. Am J Neurodegener Dis (2012) 0.89
Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord (2011) 0.89
Redox regulation in amyotrophic lateral sclerosis. Oxid Med Cell Longev (2013) 0.86
The established and emerging roles of astrocytes and microglia in amyotrophic lateral sclerosis and frontotemporal dementia. Front Cell Neurosci (2015) 0.86
NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study. Amyotroph Lateral Scler Frontotemporal Degener (2014) 0.85
A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch Neurol (1988) 0.84
Development of WF10, a novel macrophage-regulating agent. Curr Opin Investig Drugs (2002) 0.83
Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm (2015) 0.83
Thalidomide causes sinus bradycardia in ALS. J Neurol (2008) 0.81
Amyotrophic Lateral Sclerosis: New Perpectives and Update. Neurol Int (2015) 0.80
Concomitant rheumatoid arthritis and amyotrophic lateral sclerosis: report of two new cases and review of literature. Rheumatol Int (2011) 0.80
Amyotrophic lateral sclerosis and multiple sclerosis overlap: a case report. Case Rep Med (2012) 0.79
Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J Neuroinflammation (2016) 0.78
Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis. Neurotherapeutics (2016) 0.78
RNS60, a charge-stabilized nanostructure saline alters Xenopus Laevis oocyte biophysical membrane properties by enhancing mitochondrial ATP production. Physiol Rep (2015) 0.77
Amyotrophic lateral sclerosis developing during adalimumab therapy for psoriatic arthritis. Rev Neurol (Paris) (2014) 0.76
Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. J Clin Invest (2017) 0.76
Serum levels of soluble intercellular adhesion molecule-1 (s-ICAM-1) and soluble endothelial leukocyte adhesion molecule-1(s-ELAM-1) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord (2005) 0.76
Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis-A Pilot Study. PLoS One (2015) 0.76
Granulocyte colony-stimulating factor for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled study of Iranian patients. J Clin Neurol (2015) 0.76
Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's disease. Eur J Neurol (2017) 0.76
Autologous hematopoietic stem cell transplantation for MS: Safer than previously thought. Neurology (2017) 0.76
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol (2017) 0.75
Ozanezumab dose selection for amyotrophic lateral sclerosis by pharmacokinetic-pharmacodynamic modelling of immunohistochemistry data from patient muscle biopsies. PLoS One (2015) 0.75
Acute motor axonal neuropathy in a patient with prolonged CD4 depletion due to HIV: a local variant of macrophage activation syndrome? Oxf Med Case Reports (2015) 0.75